Published by The Medical Letter, Inc. • 1000 Main Street, New Rochelle, N.Y. 10801 • A Nonprofit Publication

   options

 
The Medical Letter CME Program - The Medical Letter
The purpose of The Medical Letter Continuing Medical Education Program is to provide a means for health care professionals (primarily physicians and pharmacists) to keep up to date with new drugs that are approved by the FDA, as well as keep up with the standard of care treatments for specific indications.  Specifically, the content of The Medical Letter Continuing Medical Education Program covers the mechanisms of action, pharmacokinetics, clinical trials, adverse effects, interactions, dosages and routes of administration of the drugs discussed.  Participants are required to answer exam questions based on the content of The Medical Letter.  Importantly, the objectives of developing the content on which the exam is based are to educate the participant, impact clinical practice and improve patient outcomes.  The Medical Letter's unbiased content is free of commercial influence and financial sponsorship.  The Medical Letter does not accept advertising, grants or donations.  The program is completely funded by fees paid by the exam participants. The Medical Letter CME program is accredited by:  ACCME  AAFP  ACPE
Accreditation Information and Educational Objectives for Online Series Exams
Accreditation Information and Educational Objectives for Comprehensive Exams
Copyright and Privacy Statement
Frequently Asked Questions
Active Subscribers Enroll in Free Online Series
Enrolled already? Take your next exam in the series
Switch from Print Exam to Online Exam
Continue a purchased Comprehensive Online Exam
Order Treatment Guideline CME exams

You may earn up to 26 credits per year, by choosing one of the following:

Online Series – Freely available only to active subscribers of The Medical Letter. Answer six questions per issue and submit answers online. Earn one credit/exam.  Each online series contains 13 short exams. Already enrolled and need to take next exam? Click here.   1 credit/exam; 13 credits per series Enroll in Free Online Series

Comprehensive Exam –Available online or in print to Medical Letter subscribers, this 78 question test enables you to earn 13 AMA PRA Category 1 credits immediately with the successful completion of the test. Take the exam online and receive your CME certificate within 3 business days! Our Comprehensive exams allow you to test at your own pace in the comfort of your home or office. Save airfare, conference expenses and time away from your practice.  Comprehensive tests are offered every January and July enabling you to earn up to 26 credits per year.  $22.00/13 credits

Quick One-Credit Exam – Available to both subscribers and non-subscribers. Access content and answer six questions, online only, for any available issue and earn one credit.   1 credit/exam; $12.00/credit

NOTE: Credits earned on any individual exam can not be earned again on the comprehensive exam if it covers the same material. 26 credits are the maximum you can earn in any given year.
 
CME References
Exam #56 (July 2007)
Exam #57 (January 2008)
The Medical Letter Self-Examination

Domestic
& Foreign
(U.S.D.)
Comprehensive Online Exam —each exam eligible for 13 credits, 2 exams eligible for 26 total credits. Test at your own pace in the comfort of your home or office. Save airfare, conference expenses and time away from your practice.  Earn up to 13 credits immediately.

 Exam #56 (based on issues January -June 2007)
Exam #57 (based on issues July-December 2007)
Exam #58 (based on issues January-June 2008)
      available July 15, 2008


each exam
Comprehensive Print Exam — each exam eligible for 13 credits, 2 exams eligible for 26 total credits:

 Exam #56 (based on issues January-June 2007)
Exam #57 (based on issues July-December 2007)
Exam #58 (based on issues January-June 2008)
      available July 15, 2008


each exam

Order postal copies of the 13 preceding issues
When ordering the CME comprehensive exam (print or online), issues published during the six-month period (13 issues) preceding each test may be ordered for $ .

Back issues for Exam #56
Back issues for Exam #57

Note: Institutional subscribers need not order these issues because they may be freely accessed in the online archives. Online exam customers will have online access to the articles during the test taking process.


Quick One-Credit Exam — Online Only 
I would like to order the following Online Per Issue Individual Exams eligible for 1 credit each:

1251 Sitagliptin (Januvia) for Type 2 Diabetes; Oral Oxymorphone (Opana) 
1252 Low-dose Doxycycline (Oracea) for Rosacea; Dasatinib (Sprycel) for CML and Ph+ ALL; Tdap, DTap Mix-Ups
1253 Clarification: Hand Hygiene and CDAD; Pioglitazone/Glimepiride (Duetact) for Diabetes; Telbivudine (Tyzeka) for Chronic Hepatitis B
1254 Continuous Glucose Monitoring; Angeliq for Treatment of Menopausal Symptoms
1255 Proton Pump Inhibitors for GERD in Children; Two New Drugs for Renal Cell Carcinoma; Femcon Fe: A Chewable Oral Contraceptive 
1256 Paliperidone (Invega) for Schizophrenia; Vorinostat (Zolinza) for Cutaneous T-cell Lymphoma
1257 Once-Daily Mesalamine (Lialda) for Ulcerative Colitis; Pramipexole (Mirapex) for Restless Legs Syndrome  
1258 Aliskiren (Tekturna) for Hypertension; Subcutaneous Immune Globulin (SCIG)    
1259 Drugs for Female Sexual Dysfunction; Panitumumab (Vectibix) for Metastatic Colorectal Cancer   
1260 Erythropoetin Safety Concerns; Dermal Fillers; In Brief: Tegaserod (Zelnorm) Withdrawn 
1261 A New Sunscreen Agent; Insulin-like Growth Factor-1 for Severe Growth Failure     
1262 Toxicity of Gadolinium-Based Contrast Agents; Sitagliptin/Metformin (Janumet) for Type 2 Diabetes; MoviPrep: A New Bowel Prep for Colonoscopy 
1263 Orlistat OTC for Weight Loss; Treatment of Lyme Disease; ThermaClear for Acne    
1264 Arformoterol (Brovana) for COPD; Resperate for Hypertension 
1265 Thiazolidinediones and Cardiovascular Disease; Lisdexamphetamine Dimesylate (Vyvanse) for ADHD       
1266 Lybrel – A Continuous Oral Contraceptive;  Drugs for Community-Acquired Bacterial Pneumonia  
1267 Reducing Intake of Trans Fatty Acids; Probiotics  
1268 Transdermal Rotigotine (Neupro) for Parkinson's Disease; Low-Dose Transdermal Estrogens  
1269 Tinidazole (Tindamax) - A New Option for Treatment of Bacterial Vaginosis; Lapatinib (Tykerb) for Advanced Breast Cancer; Removable Permanent Tattoo Ink  
1270 Pregabalin (Lyrica) for Fibromyalgia; Fentanyl Buccal Tablet (Fentora) for Breakthrough Pain; Eculizumab (Soliris) for Paroxysmal Nocturnal Hemoglobinuria  
1271 Influenza Vaccine 2007-2008; Blood Test for Tuberculosis  
1272 Antiviral Drugs for Influenza; Ambrisentan (Letairis) for Pulmonary Arterial Hypertension  
1273 A Once-Yearly IV Bisphosphonate for Osteoporosis; Fluticasone Furoate (Veramyst) for Allergic Rhinitis  
1274 BRCA Screening; Formoterol (Perforomist) for COPD; SSRIs and Osteoporosis  
1275 Levocetirizine (Xyzal) for Allergic Rhinitis and Urticaria; Major Changes in Endocarditis Prophylaxis for Dental, GI and GU Procedures  
1276 Two Amlodipine/ARB Combinations for Hypertension; Extended-Release Cyclobenzaprine (Amrix); Temsirolimus (Torisel) for Advanced Renal Cell Carcinoma  
1277 Cetirizine OTC; A Diclofenac Patch (Flector) for Pain; Two New Drugs for HIV Infection  
1278 Zetia and Vytorin: The ENHANCE Study; Doripenem (Doribax) - A New Parenteral Carbapenem; Ixabepilone (Ixempra) for Breast Cancer    
1279 Budesonide/Formoterol (Symbicort) for Asthma; Ophthalmic Azithromycin (AzaSite)    
1280 Retapamulin (Altabax) - A New Topical Antibiotic; Veregen: A Botanical for Treatment of Genital Warts    
1281 Nebivolol (Bystolic) for Hypertension; Gluten-Free Drugs for Celiac Disease Patients    
1282 A Rivastigmine Patch for Dementia; Palatal Implants for Snoring and Obstructive Sleep Apnea    
1283 Simcor: A Niacin/Simvastatin Combination; Nilotinib (Tasigna) for CML; Tadalafil (Cialis) Once a Day for Erectile Dysfunction    
1284 Which Statin?; Diclofenac Gel for Osteoarthritis; Genetic Test for Carbamazepine-Induced Stevens-Johnson Syndrome    
1285 Ciclesonide (Omnaris) for Allergic Rhinitis; Natalizumab (Tysabri) for Crohn's Disease    
1286 Desvenlafaxine for Depression; Pharmacogenetic-Based Dosing of Warfarin  Available 5/16/08  

$12
per credit
 
Promotional Code (if any):           
Show my current order
 

 
© 2008 The Medical Letter, Inc. All rights reserved. Use of this site signifies your agreement to the Terms and Conditions.